Earnings call transcript: Scholar Rock’s Q1 2025 results show slight EPS miss, stock reacts positively

Access earnings results, analyst expectations, report, slides, earnings call, and transcript.

Overview

The earnings call summary presents a mixed picture. Financial performance and commercial readiness are positive, with a strong cash position and launch preparations. However, concerns exist regarding regulatory risks, market access challenges, and competitive pressures. The Q&A section reveals positive payer discussions but lacks guidance on early demand, raising uncertainties. The absence of guidance and potential regulatory and market access hurdles balance the positive elements, leading to a neutral sentiment.

Key Financial Performance

Cash Position $364.4 million, an increase from the previous year, attributed to ongoing investments in commercial readiness and inventory build-out.

Debt Facility An additional $100 million available under the debt facility to support the upcoming launch, extending the anticipated runway into 2027.

You have reached the limit Upgrade to access full content

Get started

Operating Highlights

BLA Priority Review: The BLA for ipilimumab was granted priority review by the FDA with a September 22 PDUFA date.

Launch of ipilimumab: ScholarRock is preparing for the US commercial launch of ipilimumab, anticipated to commence in Q3 2025.

Exploratory cardiometabolic program: The EMBRAZE proof of concept study aims to understand the role of ScholarRock in treating obesity, with top line results expected in June 2025.

SRK439 IND Filing: ScholarRock is on track to file the IND application for SRK439 to support the first human study in Q3 2025.

Global SMA Market: ScholarRock aims to serve patients with SMA in the US, Europe, Asia Pacific, and Latin America, with nearly 35,000 patients having received SMN targeted therapies globally.

SMA Patient Demographics: In the US, there are approximately 10,000 patients with SMA, with two-thirds having received SMN targeted therapy.

Commercial Readiness: ScholarRock is building a customer-facing team of approximately 50 personnel, expected to be fully staffed by mid-2025.

Financial Position: ScholarRock ended the quarter with $364.4 million and has an additional $100 million under its debt facility to support the upcoming launch.

Expansion into Other Disorders: ScholarRock is evaluating expanding the study of upitigramab into other rare, severe, and debilitating neuromuscular disorders.

Focus on Capital Allocation: ScholarRock is prioritizing disciplined capital allocation to fuel near and long-term growth.

You have reached the limit Upgrade to access full content

Get started

Risk or Challenges

Regulatory Risks: Concerns regarding the FDA's current state and its impact on the review process for ipilimumab, although the company reports constructive interactions with the agency.

Market Access Challenges: The need for effective engagement with U.S. and ex-U.S. payers regarding coverage for combination therapies, particularly for SMA patients, which may affect market access.

Supply Chain Risks: Ensuring sufficient commercial supply for the launch of ipilimumab, with the company indicating they are working to have product available as soon as possible.

Competitive Pressures: The presence of existing SMN-targeted therapies that may impact the urgency and demand for ipilimumab, as patients are already receiving treatment.

Economic Factors: Potential implications of the recent executive order on drug pricing, which could affect pricing strategies for orphan diseases.

Clinical Development Risks: The need to demonstrate the efficacy of new therapies in the obesity space, particularly regarding muscle mass preservation, which is critical for market acceptance.

You have reached the limit Upgrade to access full content

Get started

Guidance & Outlook

BLA Priority Review: The BLA for ipilimumab was granted priority review by the FDA with a PDUFA date of September 22, 2025.

Global Launch Plans: ScholarRock is preparing for a global launch of ipilimumab, starting in the US in Q3 2025, followed by launches in Europe, Asia Pacific, and Latin America.

Expansion into Other Disorders: ScholarRock is evaluating the expansion of upitigramab into other rare, severe, and debilitating neuromuscular disorders.

EMBRACE Study: The EMBRAZE proof of concept study aims to understand the role of ScholarRock in treating obesity, with top-line results expected in June 2025.

Commercial Readiness: ScholarRock is building a commercial team and expects to be fully staffed by mid-2025, ahead of the potential launch.

Financial Position: ScholarRock ended the quarter with $364.4 million and has an additional $100 million under its debt facility to support the upcoming launch.

Capital Allocation: The company is focused on disciplined capital allocation to fuel near and long-term growth.

SMA Patient Market: There are approximately 10,000 SMA patients in the US, with two-thirds having received SMN targeted therapy.

Market Dynamics: The company expects a steady launch trajectory for ipilimumab, leveraging existing newborn screening and concentrated treatment centers.

Long-term Growth Potential: The opportunity with ipilimumab in SMA offers potential for many years of sustainable growth.

You have reached the limit Upgrade to access full content

Get started

Shareholder Return Plan

Debt Facility: Scholar Rock has an additional $100,000,000 under its debt facility that can be drawn down this year to support the upcoming launch, bringing the anticipated runway into 2027.

Cash Position: Scholar Rock ended the quarter with $364,400,000.

Commercial Readiness: Scholar Rock is prioritizing commercial launch and ongoing clinical programs, with a fully staffed U.S. market access team and customer-facing team of roughly 50 personnel expected to be in place by mid-2025.

Launch Timeline: Scholar Rock plans to launch epitigromab in the U.S. immediately after the September 22 PDUFA date.

You have reached the limit Upgrade to access full content

Get started

Key Q&A

Q:Could you just frame for us how your discussions with U.S. payers have gone? How receptive are they to coverage of combination therapy for both an SMN targeting and a muscle targeting therapy in SMA patients?

A:We would expect that the budget impact to any one single payer in the US, or even globally would be very limited for the high value proposition. Our early discussions with payers have proven to be positive and we’ll continue those discussions.

Q:Can you confirm or not if you have completed your mid-cycle meeting? And if so, can you comment on any high-level discussions you have had around labeling?

A:The conversations have been extremely constructive and right on track. Our ability today to guide on the call that we’re heading to that September 22 PDUFA date is based on a series of very constructive conversations.

Q:Are you thinking about providing more data to be a more complete package of information to help people out in terms of longer-term follow-up data on some of the metabolic parameters that could come out in June?

A:We’ll be providing the twenty-four week data. That’s the main study. We’ll certainly provide any necessary follow-up information that we have that helps us understand the potential of an anti-myostatin approach in the obesity space.

Q:How quickly will you be able to launch after the SMA approval? Will everything be completely in place already on the sales and marketing side?

A:We will be prepared to be out there the next day. I know that the supply chain team is working so that we can have product available to patients as soon as possible.

Q:Would you be able to provide any kind of metrics or guidance once the drug is approved or any color on how you see the early demand?

A:We are not going to be providing guidance at this time.

Q:How are you evaluating the potential to secure a commercial partner for Europe?

A:It is not a priority of ours to think about a partner outside of the US. We feel like there is nobody better suited to serve patients globally than us directly.

Q:Review of Unclear Management Responses

A:Management avoided providing specific metrics or guidance on early demand after drug approval, stating they are not going to be providing guidance at this time. Additionally, while they discussed payer interactions, they did not provide specific details on the outcomes of those discussions.

You have reached the limit Upgrade to access full content

Get started

Earnings Word Cloud

The most frequently occurring keywords in this quarter's earning call

SRRK Transcript

Scholar Rock Holding Corporation (SRRK) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Neutral12-3

Scholar Rock Holding Corporation (SRRK) Q3 2025 Earnings Call Transcript

Positive11-14

The earnings call summary indicates solid financial performance, strategic global expansion, and strong cash runway into 2027. The Q&A session reveals proactive risk management and strategic financing, with a focus on minimizing operational disruptions and ensuring FDA compliance. Although some uncertainties exist regarding the reinspection timeline, the company's strategic investments and optimistic guidance suggest a positive outlook. The stock price is likely to increase by 2% to 8% over the next two weeks, driven by the company's strategic initiatives and financial health.

Scholar Rock Holding Corporation (SRRK) Q2 2025 Earnings Call Transcript

Positive8-6

The earnings call highlighted strong financial health, with a significant cash runway and positive interactions with the FDA, indicating confidence in the upcoming approval of apitegromab. The management's constructive discussions with payers and plans for global expansion further support a positive outlook. Despite some uncertainties around CDMO site observations, the overall tone was optimistic, and the company's strategic initiatives are likely to bolster stock performance in the near term.

Scholar Rock Holding Corporation (NASDAQ:SRRK) Q1 2025 Earnings Call Transcript

Unknown5-15

The earnings call presents a mixed picture with several concerns: missed EPS expectations, lack of guidance, and potential financial risks due to increased expenditures. Despite positive discussions with payers and FDA, the absence of a shareholder return plan and competitive market challenges weigh negatively. The Q&A section reveals management's avoidance of specifics, adding uncertainty. While the company is prepared for a quick launch post-approval, the financial and competitive risks, combined with the missed EPS, lead to a likely negative stock reaction.

SRRK Slides

Scholar Rock Q2 2025 slides: Apitegromab nears FDA decision with strong cash position

2025-08-06

SRRK Report

Scholar Rock Holding Corp 10-Q

10-Q

2024-11-12

Scholar Rock Holding Corp 10-Q

10-Q

2024-08-08

Scholar Rock Holding Corp 10-Q

10-Q

2024-05-07

Scholar Rock Holding Corp 10-K

10-K

2024-03-19

Frequently Asked Questions

Where does this earnings call transcript come from?

All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.

How soon is the transcript available after the earnings call ends?

Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.

Is the transcript edited or altered in any way?

No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.

Why do some answers appear as “Unclear” or “Inaudible”?

When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.

Who creates the AI Summary and Key Q&A highlights shown above the transcript?

They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.